This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (14)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Adverse Effects  • Alert me on articles by topic

Laila Akhund, MD; Robert J. Quinet, MD; Saliha Ishaq, MD

Arch Intern Med. 2003;163:114-115.

Selective cyclooxygenase 2 (COX-2) inhibitors are known to affect renal prostaglandins (epoprostenol and dinoprostone), which are at least in part COX-2 dependent. Consequently, adverse events including hypertension, peripheral edema, hypercalemia, hyponatremia, and acute renal failure have been reported to occur with the new COX-2–specific inhibitors. This case report posits celecoxib as a likely cause of renal papillary necrosis and alerts physicians to the possibility of this additional renal complication with COX-2–specific inhibitors.

From the Department of Internal Medicine, Section on Rheumatology, Ochsner Clinic Foundation, New Orleans, La.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Update on Cyclooxygenase-2 Inhibitors
Harris and Breyer
CJASN 2006;1:236-245.
ABSTRACT | FULL TEXT  

Prostacyclin signaling in the kidney: implications for health and disease
Nasrallah and Hebert
Am. J. Physiol. Renal Physiol. 2005;289:F235-F246.
ABSTRACT | FULL TEXT